These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18290962)

  • 1. Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
    Peter S; Hausmann N; Schuster A; Boehm HF
    Clin Exp Ophthalmol; 2008; 36(1):94-6. PubMed ID: 18290962
    [No Abstract]   [Full Text] [Related]  

  • 2. [Reversible posterior leukoencephalopathy syndrome associated to bevacizumab].
    Ortiz-Lopez EM; Gonzalez-Nieto JA; Rojas-Marcos I; Blanco-Ollero A
    Rev Neurol; 2010 Jul; 51(2):117-8. PubMed ID: 20602317
    [No Abstract]   [Full Text] [Related]  

  • 3. Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    J Ocul Pharmacol Ther; 2010 Jun; 26(3):301-3. PubMed ID: 20565319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posterior reversible encephalopathy syndrome with bevacizumab.
    Lau PC; Paunipagar B
    Hong Kong Med J; 2011 Feb; 17(1):80-1. PubMed ID: 21282833
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case.
    Koopman M; Muller EW; Punt CJ
    Dis Colon Rectum; 2008 Sep; 51(9):1425-6. PubMed ID: 18470563
    [No Abstract]   [Full Text] [Related]  

  • 6. Hand eruption after intravenous administration of bevacizumab.
    Ruiz V; Garcia-Muret MP; Alomar A
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):238-9. PubMed ID: 20477919
    [No Abstract]   [Full Text] [Related]  

  • 7. Isolated brainstem involvement in posterior reversible leukoencephalopathy induced by bevacizumab.
    El Maalouf G; Mitry E; Lacout A; Lièvre A; Rougier P
    J Neurol; 2008 Feb; 255(2):295-6. PubMed ID: 18283405
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
    Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
    J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
    [No Abstract]   [Full Text] [Related]  

  • 9. Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
    Abbas O; Shamseddin A; Temraz S; Haydar A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23436889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer.
    Allen JA; Adlakha A; Bergethon PR
    Arch Neurol; 2006 Oct; 63(10):1475-8. PubMed ID: 17030665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benign reversible encephalopathy syndrome after bevacizumab therapy for metastatic ovarian cancer.
    Sawaya R; Radwan W; Hammoud S
    Med Oncol; 2014 Feb; 31(2):831. PubMed ID: 24385223
    [No Abstract]   [Full Text] [Related]  

  • 12. [Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma].
    Fieth C; Kebig A; Mohr K
    Pharm Unserer Zeit; 2007; 36(6):442-5. PubMed ID: 17957688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Posterior Reversible Encephalopathy Syndrome (PRES): About 4 cases].
    Chanal E; Bouleftour W; Rivoirard R; Bosaki C; Forges F; Jacquin JP; Fournel P; Mery B; Saban-Roche L
    Presse Med; 2019 Oct; 48(10):1026-1031. PubMed ID: 31653541
    [No Abstract]   [Full Text] [Related]  

  • 14. Metrorrhagia after intravitreal injection of bevacizumab.
    Rodrigues EB; Shiroma H; Meyer CH; Maia M; Farah ME
    Acta Ophthalmol Scand; 2007 Dec; 85(8):915-6. PubMed ID: 17645422
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
    Bürki F; Badie K; Bartoli P; Bernard P; Montastruc JL; Bagheri H
    Br J Clin Pharmacol; 2008 May; 65(5):793-4. PubMed ID: 18279475
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of bevacizumab in mild haemophilia B.
    Lambert C; Deneys V; Pothen D; Hermans C
    Thromb Haemost; 2008 May; 99(5):963-4. PubMed ID: 18449429
    [No Abstract]   [Full Text] [Related]  

  • 17. Bevacizumab: improved survival at what cost?
    Kolesar JM
    Am J Health Syst Pharm; 2005 May; 62(10):1017. PubMed ID: 15901584
    [No Abstract]   [Full Text] [Related]  

  • 18. [Molecular target therapy for colonic neoplasms].
    Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
    Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
    [No Abstract]   [Full Text] [Related]  

  • 19. Nonconvulsive status epilepticus related to posterior reversible leukoencephalopathy syndrome induced by cetuximab.
    Palma JA; Gomez-Ibañez A; Martin B; Urrestarazu E; Gil-Bazo I; Pastor MA
    Neurologist; 2011 Sep; 17(5):273-5. PubMed ID: 21881470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab.
    Levy CF; Oo KZ; Fireman F; Pierre L; Bania MA; Sadanandan S; Yamashiro DJ; Glade Bender JL
    Pediatr Blood Cancer; 2009 May; 52(5):669-71. PubMed ID: 19101996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.